D. E. Shaw & Co., Inc. Incyte Corp Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Incyte Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,108,573 shares of INCY stock, worth $76.5 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

1,108,573

Holding current value

$76.5 Million

% of portfolio

0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $7.15 Million - $8.55 Million	-124,644 Reduced 10.11%	1,108,573 $73.3 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $7.8 Million - $9.71 Million	-152,376 Reduced 11.0%	1,233,217 $74.8 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $6.53 Million - $7.69 Million	-115,431 Reduced 7.69%	1,385,593 $78.9 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $9.15 Million - $11.3 Million	-175,346 Reduced 10.46%	1,501,024 $94.2 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $7.46 Million - $8.51 Million	-129,144 Reduced 7.15%	1,676,370 $96.8 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $56.8 Million - $70.3 Million	931,571 Added 106.59%	1,805,514 $112 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $5.13 Million - $6.28 Million	72,980 Added 9.11%	873,943 $63.2 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $1.28 Million - $1.6 Million	-19,022 Reduced 2.32%	800,963 $64.3 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $45.2 Million - $56.6 Million	-682,771 Reduced 45.43%	819,985 $54.6 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $44.8 Million - $56.4 Million	-677,622 Reduced 31.08%	1,502,756 $114 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $25.5 Million - $30.8 Million	-386,189 Reduced 15.05%	2,180,378 $173 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $48.7 Million - $56.9 Million	768,232 Added 42.72%	2,566,567 $188 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $96.9 Million - $119 Million	1,410,796 Added 364.04%	1,798,335 $124 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $4.24 Million - $4.64 Million	-53,029 Reduced 12.04%	387,539 $32.6 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $7.56 Million - $10 Million	99,456 Added 29.16%	440,568 $35.8 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $552,100 - $668,072	6,838 Added 2.05%	341,112 $29.7 Million
Q3 2020 Nov 16, 2020	BUY	$85.07 - $109.69 $8.87 Million - $11.4 Million	104,286 Added 45.34%	334,274 $30 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $27.3 Million - $40.1 Million	-368,156 Reduced 61.55%	229,988 $23.9 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $14.3 Million - $19.5 Million	-226,540 Reduced 27.47%	598,144 $43.8 Million
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $23.8 Million - $31.2 Million	-325,448 Reduced 28.3%	824,684 $72 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $4.34 Million - $5.16 Million	-59,620 Reduced 4.93%	1,150,132 $85.4 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $10.6 Million - $12.8 Million	144,525 Added 13.57%	1,209,752 $103 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $13.8 Million - $19.1 Million	-216,838 Reduced 16.91%	1,065,227 $91.6 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $32.8 Million - $39.2 Million	560,560 Added 77.69%	1,282,065 $81.5 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $24.6 Million - $29.5 Million	398,087 Added 123.09%	721,505 $49.8 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $16.7 Million - $23 Million	273,750 Added 551.16%	323,418 $21.7 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $4.13 Million - $5.02 Million	49,668 New	49,668 $4.14 Million

Others Institutions Holding INCY

# of Institutions

690

Shares Held

190M

Call Options Held

685K

Put Options Held

533K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account